<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01785732</url>
  </required_header>
  <id_info>
    <org_study_id>SA-007</org_study_id>
    <nct_id>NCT01785732</nct_id>
  </id_info>
  <brief_title>Renal Sympathetic Denervation and Insulin Sensitivity (RENSYMPIS Study)</brief_title>
  <acronym>RENSYMPIS</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital District of Satakunta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital District of Satakunta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertension is a major risk factor for stroke and cardiovascular mortality. Catheter- based
      renal denervation causes substantial and sustained blood- pressure reduction in patients with
      resistant hypertension.

      The purpose of RENSYMPIS is to study the effects of renal denervation on:

        1. Cardiovascular function

        2. Metabolic factors

        3. Inflammatory and endocrine factors

        4. Coagulation

        5. Sleep
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Office blood pressure</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Resistant Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal denervation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are randomized to renal denervation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimization of medical therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Antihypertensive treatment is optimized</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal Denervation</intervention_name>
    <description>Sympathetic renal denervation via renal arteries</description>
    <arm_group_label>Renal denervation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resistant Hypertension (systolic blood pressure &gt;160mmHg and 3 or more
             antihypertensive agents in use)

          -  Age 30- 69 years

          -  Written informed consent

        Exclusion Criteria:

          -  Secondary hypertension

          -  Pseudohypertension

          -  Pregnancy

          -  Renal insufficiency (GFR &lt;45ml/min)

          -  Clinically significant stenotic valvular disease

          -  Oral anticoagulation

          -  CCS III-IV symptoms or CABG/PCI in previous 6 months

          -  Prior stroke

          -  Contrast agent allergy

          -  inappropriate renal artery anatomy (&lt; 4mm diameter, &lt; 20mm length)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tuomas Paana, M.D.</last_name>
    <phone>+358 2 6277100</phone>
    <email>tuomas.paana@satshp.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antti Ylitalo, M.D. Ph.D</last_name>
    <phone>+358 2 6277100</phone>
    <email>antti.ylitalo@satshp.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Satakunta Central Hospital</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuomas Paana, M.D</last_name>
      <phone>+358 2 6277100</phone>
      <email>tuomas.paana@satshp.fi</email>
    </contact>
    <investigator>
      <last_name>Tuomas Paana, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antti Ylitalo, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Risto Kaaja, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2013</study_first_submitted>
  <study_first_submitted_qc>February 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2013</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

